Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with ...
Processa Pharmaceuticals, Inc. (NASDAQ Capital Market: PCSA) is a clinical-stage biopharmaceutical company headquartered in Hanover, Maryland. The company’s purpose is to identify and advance therapeutic agents that aim to improve survival and/or quality of life for patients who have significant unmet medical needs. Its strategy emphasizes developing drug candidates with ...Processa Pharmaceuticals, Inc. (NASDAQ Capital Market: PCSA) is a clinical-stage biopharmaceutical company headquartered in Hanover, Maryland. The company’s purpose is to identify and advance therapeutic agents that aim to improve survival and/or quality of life for patients who have significant unmet medical needs. Its strategy emphasizes developing drug candidates with existing clinical evidence of efficacy where possible, and progressing them through well-defined clinical development programs.
From a business perspective, Processa operates in the high-risk, capital-intensive environment typical of small-cap biotechnology companies. With a relatively small workforce (about 12 full-time employees reported), the company is structured to carry out core functions such as clinical operations support, regulatory strategy, and the execution of clinical trials, often relying on external partners and specialized vendors common across the sector.
Product-wise, Processa’s pipeline includes multiple investigational programs across oncology and other specialty indications. The company’s leading investigational drug, PCS499, is an oral tablet in Phase 2B clinical assessment intended to address ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Its portfolio also includes PCS12852, a selective 5-HT4 receptor agonist currently in Phase 2A for gastrointestinal motility-related disorders such as gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia.
In oncology-focused development, Processa is advancing PCS3117, a cytosine analog that has reached Phase 2B clinical trials for pancreatic cancer and non-small cell lung cancer. It is also developing PCS6422, an oral, potent, selective, irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), which is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. Additionally, the company is developing PCS11T, an analog derived from SN38 and irinotecan, intended for a range of cancer types.
Cost and financial considerations for companies like Processa typically center on clinical trial expenses (patient recruitment, monitoring, drug supply, and compliance), regulatory and quality systems, and ongoing R&D overhead. As many development-stage biopharmaceutical companies prioritize trial progression over near-term revenue generation, financial performance can be volatile and highly dependent on funding availability, milestone achievements, and successful continuation of clinical studies.
Key leadership includes CEO George K. Ng, with additional board and management involvement reflecting experience in biotech and drug development. Overall, Processa’s near- to mid-term “wish” (in the sense of corporate execution goals) is to advance its clinical-stage pipeline through further trial milestones, validate therapeutic potential in targeted indications, and increase shareholder value through credible clinical results and progress toward potential commercialization pathways.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-13.6M
-14.5%
+3.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-11.4M
-1.2%
+58.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
-100.0%
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.54x
+107.4%
-11.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
